The test is based on glycosylated hemoglobin (HbA1c) as a marker, which is preoteolytically digested and selectively oxidized by a proprietary fructosyl peptide oxidase developed by Kikkoman. The procedure won a prize at the 22nd Annual Meeting of the Japanese Society for Fermentation and Bioengineering presently held in Hiroshima.
Kikkoman press release, Sept. 12, 2013
Kikkoman presents novel enzyme assay for rapid early diagnosis of diabetics